Nodal recurrences after stereotactic body radiotherapy for early stage non–small-cell lung cancer

Ginsberg, 1995, Randomized trial of lobectomy versus limited resection for T1N0 non-small cell lung cancer, Ann Thorac Surg, 60, 615, 10.1016/0003-4975(95)00537-U Chang, 2015, Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials, Lancet Oncol, 16, 630, 10.1016/S1470-2045(15)70168-3 Cao, 2019, A systematic review and meta-analysis of stereotactic body radiation therapy versus surgery for patients with non–small cell lung cancer, J Thorac Cardiovasc Surg, 157, 362, 10.1016/j.jtcvs.2018.08.075 Timmerman, 2014, Long-term results of RTOG 0236: a phase II trial of stereotactic body radiation therapy (SBRT) in the treatment of patients with medically inoperable stage I non-small cell lung cancer, Int J Radiat Oncol, 90, S30, 10.1016/j.ijrobp.2014.05.135 Nagata, 2015, Prospective trial of stereotactic body radiation therapy for both operable and inoperable T1N0M0 non-small cell lung cancer: Japan Clinical Oncology Group Study JCOG0403, Int J Radiat Oncol Biol Phys, 93, 989, 10.1016/j.ijrobp.2015.07.2278 Dales, 1990, Computed tomography to stage lung cancer. Approaching a controversy using meta-analysis, Am Rev Respir Dis, 141, 1096, 10.1164/ajrccm/141.5_Pt_1.1096 Robinson, 2013, Patterns of failure after stereotactic body radiation therapy or lobar resection for clinical stage I non-small-cell lung cancer, J Thorac Oncol, 8, 192, 10.1097/JTO.0b013e31827ce361 Bradley, 2010, Stereotactic body radiation therapy for early-stage non-small-cell lung cancer: the pattern of failure is distant, Int J Radiat Oncol Biol Phys, 77, 1146, 10.1016/j.ijrobp.2009.06.017 Dwamena, 1999, Metastases from non-small cell lung cancer: mediastinal staging in the 1990s—meta-analytic comparison of PET and CT, Radiology, 213, 530, 10.1148/radiology.213.2.r99nv46530 Ward, 2016, Isolated nodal failure after stereotactic body radiotherapy for lung cancer: the role for salvage mediastinal radiotherapy, J Thorac Oncol, 11, 1558, 10.1016/j.jtho.2016.05.003 Shaverdian, 2016, Pretreatment anemia portends poor survival and nonlocal disease progression in patients with stage I non-small cell lung cancer treated with stereotactic body radiation therapy, J Thorac Oncol, 11, 1319, 10.1016/j.jtho.2016.04.030 Crabtree, 2014, Analysis of first recurrence and survival in patients with stage I non-small cell lung cancer treated with surgical resection or stereotactic radiation therapy, J Thorac Cardiovasc Surg, 147, 1183, 10.1016/j.jtcvs.2013.11.057 Grills, 2010, Outcomes after stereotactic lung radiotherapy or wedge resection for stage I non-small-cell lung cancer, J Clin Oncol, 28, 928, 10.1200/JCO.2009.25.0928 Nyman, 2016, SPACE—a randomized study of SBRT vs conventional fractionated radiotherapy in medically inoperable stage I NSCLC, Radiother Oncol, 121, 1, 10.1016/j.radonc.2016.08.015 Ball, 2019, Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial, Lancet Oncol, 20, 494, 10.1016/S1470-2045(18)30896-9 Spratt, 2016, Recurrence patterns and second primary lung cancers after stereotactic body radiation therapy for early-stage non-small-cell lung cancer: implications for surveillance this work was presented at the 56th Annual Meeting of the American Society for Radiation, Clin Lung Cancer, 17, 177, 10.1016/j.cllc.2015.09.006 Kennedy, 2020, Impact of invasive nodal staging on regional and distant recurrence rates after SBRT for inoperable stage I NSCLC, Radiother Oncol, 150, 206, 10.1016/j.radonc.2020.06.043 Lagerwaard, 2008, Outcomes of risk-adapted fractionated stereotactic radiotherapy for stage I non-small-cell lung cancer, Int J Radiat Oncol Biol Phys, 70, 685, 10.1016/j.ijrobp.2007.10.053 Nagata, 2015, Prospective trial of stereotactic body radiation therapy for both operable and inoperable T1N0M0 non-small cell lung cancer: Japan Clinical Oncology Group Study JCOG0403, Int J Radiat Oncol Biol Phys, 93, 989, 10.1016/j.ijrobp.2015.07.2278 Ricardi, 2014, Stereotactic ablative radiotherapy for stage I histologically proven non-small cell lung cancer: an Italian multicenter observational study, Lung Cancer, 84, 248, 10.1016/j.lungcan.2014.02.015 Senthi, 2012, Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer: a retrospective analysis, Lancet Oncol, 13, 802, 10.1016/S1470-2045(12)70242-5 Lagerwaard, 2008, Outcomes of risk-adapted fractionated stereotactic radiotherapy for stage I non-small-cell lung cancer, Int J Radiat Oncol Biol Phys, 70, 685, 10.1016/j.ijrobp.2007.10.053 Lin, 2019, Outcomes of stereotactic body radiotherapy versus lobectomy for stage I non-small cell lung cancer: a propensity score matching analysis, BMC Pulm Med, 19, 1, 10.1186/s12890-019-0858-y Robson, 2014, Occult nodal disease in patients with non-small-cell lung cancer who are suitable for stereotactic ablative body radiation, Clin Lung Cancer, 15, 466, 10.1016/j.cllc.2014.07.006 Vial, 2017, Endobronchial ultrasound-guided transbronchial needle aspiration in the nodal staging of stereotactic ablative body radiotherapy patients, Ann Thorac Surg, 103, 1600, 10.1016/j.athoracsur.2016.09.106 Videtic, 2019, Long-term follow-up on NRG oncology RTOG 0915 (NCCTG N0927): a randomized phase 2 study comparing 2 stereotactic body radiation therapy schedules for medically inoperable patients with stage I peripheral non-small cell lung cancer, Int J Radiat Oncol Biol Phys, 103, 1077, 10.1016/j.ijrobp.2018.11.051 Bezjak, 2016, Efficacy and toxicity analysis of NRG oncology/RTOG 0813 trial of stereotactic body radiation therapy (SBRT) for centrally located non-small cell lung cancer (NSCLC), Int J Radiat Oncol, 96, S8, 10.1016/j.ijrobp.2016.06.035 Sun, 2017, 7-year follow-up after stereotactic ablative radiotherapy for patients with stage I non–small cell lung cancer: results of a phase 2 clinical trial, Cancer, 123, 3031, 10.1002/cncr.30693 Lagerwaard, 2012, Outcomes of stereotactic ablative radiotherapy in patients with potentially operable stage I non-small cell lung cancer, Int J Radiat Oncol Biol Phys, 83, 348, 10.1016/j.ijrobp.2011.06.2003 Baumann, 2009, Outcome in a prospective phase II trial of medically inoperable stage I non-small-cell lung cancer patients treated with stereotactic body radiotherapy, J Clin Oncol, 27, 3290, 10.1200/JCO.2008.21.5681 Olsen, 2011, Dose-response for stereotactic body radiotherapy in early-stage non-small-cell lung cancer, Int J Radiat Oncol Biol Phys, 81, 299, 10.1016/j.ijrobp.2011.01.038 Schonewolf, 2018, Outcomes of invasive mediastinal nodal staging versus positron emission tomography staging alone for early-stage non-small cell lung cancer treated with stereotactic body radiation therapy, Lung Cancer, 117, 53, 10.1016/j.lungcan.2017.07.005 Onishi, 2011, Stereotactic body radiotherapy (SBRT) for operable stage I non-small-cell lung cancer: can SBRT be comparable to surgery?, Int J Radiat Oncol Biol Phys, 81, 1352, 10.1016/j.ijrobp.2009.07.1751 De Leyn, 2014, Revised ESTS guidelines for preoperative mediastinal lymph node staging for non-small-cell lung cancer, Eur J Cardiothorac Surg, 45, 787, 10.1093/ejcts/ezu028 Schneider, 2018, Stereotactic body radiotherapy for early-stage non-small-cell lung cancer: American Society of Clinical Oncology endorsement of the American Society for Radiation Oncology evidence-based guideline, J Clin Oncol, 36, 710, 10.1200/JCO.2017.74.9671 Pignon, 2008, Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE collaborative group, J Clin Oncol, 26, 3552, 10.1200/JCO.2007.13.9030 Stephans, 2018, Tumor control and toxicity for common stereotactic body radiation therapy dose-fractionation regimens in stage I non-small cell lung cancer, Int J Radiat Oncol Biol Phys, 100, 462, 10.1016/j.ijrobp.2017.10.037 Timmerman, 2010, Stereotactic body radiation therapy for inoperable early stage lung cancer, JAMA, 303, 1070, 10.1001/jama.2010.261 Lao, 2014, Incidental prophylactic nodal irradiation and patterns of nodal relapse in inoperable early stage NSCLC patients treated with SBRT: a case-matched analysis, Int J Radiat Oncol Biol Phys, 90, 209, 10.1016/j.ijrobp.2014.05.006 Baine, 2018, Histology significantly affects recurrence and survival following SBRT for early stage non-small cell lung cancer, Lung Cancer, 118, 20, 10.1016/j.lungcan.2018.01.021 Li, 2013, Risk factors for predicting the occult nodal metastasis in T1-2N0M0 NSCLC patients staged by PET/CT: potential value in the clinic, Lung Cancer, 81, 213, 10.1016/j.lungcan.2013.04.012 Ye, 2014, Predictive factors for lymph node metastasis in clinical stage IA lung adenocarcinoma, Ann Thorac Surg, 98, 217, 10.1016/j.athoracsur.2014.03.005 Miyasaka, 2013, The maximum standardized uptake value of fluorodeoxyglucose positron emission tomography of the primary tumour is a good predictor of pathological nodal involvement in clinical N0 non-small-cell lung cancer, Eur J Cardiothorac Surg, 44, 83, 10.1093/ejcts/ezs604 Park, 2010, Occult nodal metastasis in patients with non-small cell lung cancer at clinical stage IA by PET/CT, Respirology, 15, 1179, 10.1111/j.1440-1843.2010.01793.x Nambu, 2009, Relationship between maximum standardized uptake value (SUVmax) of lung cancer and lymph node metastasis on FDG-PET, Ann Nucl Med, 23, 269, 10.1007/s12149-009-0237-5 Wang, 2020, Clinical significance of PET/CT uptake for peripheral clinical N0 non-small cell lung cancer, Cancer Med, 9, 2445, 10.1002/cam4.2900 Van Tinteren, 2002, Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial, Lancet, 359, 1388, 10.1016/S0140-6736(02)08352-6 Pak, 2015, Update on nodal staging in non-small cell lung cancer with integrated positron emission tomography/computed tomography: a meta-analysis, Ann Nucl Med, 29, 409, 10.1007/s12149-015-0958-6 Lv, 2011, Diagnostic performance of integrated positron emission tomography/computed tomography for mediastinal lymph node staging in non-small cell lung cancer: a bivariate systematic review and meta-analysis, J Thorac Oncol, 6, 1350, 10.1097/JTO.0b013e31821d4384 Billé, 2009, Preoperative intrathoracic lymph node staging in patients with non-small-cell lung cancer: accuracy of integrated positron emission tomography and computed tomography, Eur J Cardiothorac Surg, 36, 440, 10.1016/j.ejcts.2009.04.003 Li, 2012, Mediastinal lymph nodes staging by 18F-FDG PET/CT for early stage non-small cell lung cancer: a multicenter study, Radiother Oncol, 102, 246, 10.1016/j.radonc.2011.10.016 Akthar, 2017, Limitations of PET/CT in the detection of occult N1 metastasis in clinical stage I (T1-2aN0) non-small cell lung cancer for staging prior to stereotactic body radiotherapy, Technol Cancer Res Treat, 16, 15, 10.1177/1533034615624045 Hashimoto, 2018, The role of endobronchial ultrasound-guided transbronchial needle aspiration in stereotactic body radiation therapy for non-small cell lung cancer, Lung Cancer, 123, 1, 10.1016/j.lungcan.2018.06.011 Ghaly, 2017, Clinical predictors of nodal metastases in peripherally clinical T1a N0 non-small cell lung cancer, Ann Thorac Surg, 104, 1153, 10.1016/j.athoracsur.2017.02.074 Tsutani, 2012, Prediction of pathologic node-negative clinical stage IA lung adenocarcinoma for optimal candidates undergoing sublobar resection, J Thorac Cardiovasc Surg, 144, 1365, 10.1016/j.jtcvs.2012.07.012 Seok, 2014, Frequency of lymph node metastasis according to the size of tumors in resected pulmonary adenocarcinoma with a size of 30 mm or smaller, J Thorac Oncol, 9, 818, 10.1097/JTO.0000000000000169 Ding, 2018, Predictors of lymph node metastasis and possible selective lymph node dissection in clinical stage IA non-small cell lung cancer, J Thorac Dis, 10, 4061, 10.21037/jtd.2018.06.129 Manabe, 2018, Definitive radiotherapy for hilar and/or mediastinal lymph node metastases after stereotactic body radiotherapy or surgery for stage I non-small cell lung cancer: 5-year results, Jpn J Radiol, 36, 719, 10.1007/s11604-018-0776-6 Horne, 2018, Stereotactic body radiation therapy for isolated hilar and mediastinal non-small cell lung cancers, Lung Cancer, 115, 1, 10.1016/j.lungcan.2017.10.014 Chen, 2008, Dose-individualized stereotactic body radiotherapy for T1-3N0 non-small cell lung cancer: long-term results and efficacy of adjuvant chemotherapy, Radiother Oncol, 88, 351, 10.1016/j.radonc.2008.07.013 Kann, 2019, Stereotactic body radiotherapy with adjuvant systemic therapy for early-stage non-small cell lung carcinoma: a multi-institutional analysis, Radiother Oncol, 132, 188, 10.1016/j.radonc.2018.10.017 Ernani, 2019, Adjuvant systemic therapy in patients with early-stage NSCLC treated with stereotactic body radiation therapy, J Thorac Oncol, 14, 475, 10.1016/j.jtho.2018.11.018 Verma, 2017, Stereotactic body radiation therapy and the influence of chemotherapy on overall survival for large (≥5 centimeter) non-small cell lung cancer, Int J Radiat Oncol Biol Phys, 97, 146, 10.1016/j.ijrobp.2016.09.036 Complete endosonographic intrathoracic nodal staging of lung cancer patients in whom SABR is considered. Available at:https://clinicaltrials.gov/ct2/show/NCT02997449. Accessed June 11, 2020. Endobronchial ultrasound-guided transbronchial needle aspiration for lymph node staging in patients with non-small cell lung cancer pursuing stereotactic body radiotherapy (SBRT). Available at: https://clinicaltrials.gov/ct2/show/NCT01786590?id=NCT02719847+OR+NCT01786590+OR+NCT02997449&draw=2&rank=3&load=cart. Accessed June 11, 2020.